The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms

Journal of Urology

Volumn 187, Issue 5, 2012, Pages 1721-1726

  Staskin, David R ^a   Michel, Martin C ^b   Sun, Franklin ^c   Guan, Zhonghong ^c   Morrow, Jon D ^d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c PFIZER INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

dose response relationship; drug; fesoterodine; muscarinic antagonists; overactive; placebo effect; urinary bladder

Indexed keywords

FESOTERODINE; PLACEBO;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; NAUSEA; OVERACTIVE BLADDER; PLACEBO EFFECT; POST HOC ANALYSIS; PRIORITY JOURNAL; SELF REPORT; SHAM PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PLACEBO EFFECT; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 84859518682     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.12.052     Document Type: Article

References (26)

1. C.R. Chapple, V. Khullar, Z. Gabriel The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 2008 543
2. K.E. Andersson, C.R. Chapple, L. Cardozo Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence Curr Opin Urol 19 2009 380
3. Enablex® (darifenacin hydrobromide) Full Prescribing Information 2008 Novartis Pharma Stein Stein, Switzerland
4. Toviaz (fesoterodine) Full Prescribing Information 2008 Pfizer New York
5. VESIcare® (solifenacin succinate) Full Prescribing Information 2008 GlaxoSmithKline Norman: Astellas Pharma and Research Triangle Park
6. J.H.S. van Leeuwen, R. Castro, M. Busse The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms Eur Urol 50 2006 440
7. S. Lee, B. Malhotra, D. Creanga A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder BMC Med Res Methodol 9 2009 55
8. C.R. Chapple, R. Martinez-Garcia, L. Selvaggi A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial Eur Urol 48 2005 464
9. W. Steers, J. Corcos, J. Foote An investigation of dose titration with darifenacin, an M-selective receptor antagonist BJU Int 95 2005 580
10. R.R. Dmochowski, K.M. Peters, J.D. Morrow Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder Urology 75 2010 62
11. M.M. Karram, M.R. Toglia, S.R. Serels Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial Urology 73 2009 14
12. L. Cardozo, E. Hessdorfer, R. Milani Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial BJU Int 102 2008 1120
13. K.S. Coyne, L.S. Matza, Z. Kopp The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder Eur Urol 49 2006 1079
14. K.S. Coyne, M.K. Margolis, R. Hsieh Validation of the urinary sensation scale (USS) Neurourol Urodyn 30 2011 360
15. L. Cardozo, K.S. Coyne, E. Versi Validation of the Urgency Perception Scale BJU Int 95 2005 591
16. A.A. Mangoni, S.H. Jackson Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications Br J Clin Pharmacol 57 2004 6
17. C.R. Chapple, M.T. Rosenberg, F.J. Brenes Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome BJU Int 104 2009 960
18. M.C. Michel, D. Staskin Understanding dose titration: overactive bladder treatment with fesoterodine as an example Eur Urol 10 suppl. 2011 8
19. D.G. Finniss, T.J. Kaptchuk, F. Miller Biological, clinical, and ethical advances of placebo effects Lancet 375 2010 686
20. D.R. Staskin The placebo response: not very pleasing Curr Bladder Dysfunct Rep 5 2010 1
21. D. Staskin, V. Khullar, M.C. Michel Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder Neurourol Urodyn 30 2011 1480
22. N. Andre-Obadia, M. Magnin, L. Garcia-Larrea On the importance of placebo timing in rTMS studies for pain relief Pain 152 2011 1233
23. K. Hewett, M.D. Gee, A. Krishen Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR J Psychopharmacol 24 2010 1209
24. M. Silver, D. Blum, J. Grainger Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain J Pain Symptom Manage 34 2007 446
25. A.L. Geers, K. Kosbab, S.G. Helfer Further evidence for individual differences in placebo responding: an interactionist perspective J Psychosom Res 62 2007 563
26. J.F. Wyman, G. Harding, C. Klutke Contributors to satisfaction with combined drug and behavioral therapy for overactive bladder in subjects dissatisfied with prior drug treatment J Wound Ostomy Continence Nurs 37 2010 199